Plant-based production of highly potent anti-HIV antibodies with engineered posttranslational modifications.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
10 04 2020
Historique:
received: 05 07 2019
accepted: 17 03 2020
entrez: 12 4 2020
pubmed: 12 4 2020
medline: 15 12 2020
Statut: epublish

Résumé

Broadly neutralising antibodies (bNAbs) against human immunodeficiency virus type 1 (HIV-1), such as CAP256-VRC26 are being developed for HIV prevention and treatment. These Abs carry a unique but crucial post-translational modification (PTM), namely O-sulfated tyrosine in the heavy chain complementarity determining region (CDR) H3 loop. Several studies have demonstrated that plants are suitable hosts for the generation of highly active anti-HIV-1 antibodies with the potential to engineer PTMs. Here we report the expression and characterisation of CAP256-VRC26 bNAbs with posttranslational modifications (PTM). Two variants, CAP256-VRC26 (08 and 09) were expressed in glycoengineered Nicotiana benthamiana plants. By in planta co-expression of tyrosyl protein sulfotransferase 1, we installed O-sulfated tyrosine in CDR H3 of both bNAbs. These exhibited similar structural folding to the mammalian cell produced bNAbs, but non-sulfated versions showed loss of neutralisation breadth and potency. In contrast, tyrosine sulfated versions displayed equivalent neutralising activity to mammalian produced antibodies retaining exceptional potency against some subtype C viruses. Together, the data demonstrate the enormous potential of plant-based systems for multiple posttranslational engineering and production of fully active bNAbs for application in passive immunisation or as an alternative for current HIV/AIDS antiretroviral therapy regimens.

Identifiants

pubmed: 32277089
doi: 10.1038/s41598-020-63052-1
pii: 10.1038/s41598-020-63052-1
pmc: PMC7148297
doi:

Substances chimiques

Antibodies, Neutralizing 0
HIV Antibodies 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6201

Références

UNAIDS. Fact sheet - Latest statistics on the status of the AIDS epidemic | UNAIDS. Available at: http://www.unaids.org/en/resources/fact-sheet . (Accessed: 9th May 2018) (2018).
Klein, F. et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492, 118–22 (2012).
doi: 10.1038/nature11604
Doria-Rose, N. A. et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509, 55–62 (2014).
doi: 10.1038/nature13036
McLellan, J. S. et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480, 336–343 (2011).
Choe, H. et al. Tyrosine Sulfation of Human Antibodies Contributes to Recognition of the CCR5 Binding Region of HIV-1 gp120. Cell 114, 161–170 (2003).
doi: 10.1016/S0092-8674(03)00508-7
Lin, H., Du, J. & Jiang, H. Modifications to Regulate Protein Function. https://doi.org/10.1002/9780470048672.wecb467 (2008).
Rosenberg, Y. et al. Pharmacokinetics and Immunogenicity of Broadly Neutralizing HIV Monoclonal Antibodies in Macaques. PLoS One 10, 1–15 (2015).
Moore, K. L. Protein tyrosine sulfation: a critical posttranslation modification in plants and animals. Proc. Natl. Acad. Sci. USA 106, 14741–14742 (2009).
doi: 10.1073/pnas.0908376106
Stone, M. J., Chuang, S., Hou, X., Shoham, M. & Zhu, J. Z. Tyrosine sulfation: an increasingly recognised post-translational modification of secreted proteins. N. Biotechnol. 25, 299–317 (2009).
doi: 10.1016/j.nbt.2009.03.011
Nandi, S. et al. Techno-economic analysis of a transient plant-based platform for monoclonal antibody production. MAbs 8, 1456–1466 (2016).
doi: 10.1080/19420862.2016.1227901
Schähs, M. et al. Production of a monoclonal antibody in plants with a humanized N-glycosylation pattern. Plant Biotechnol. J. 5, 657–663 (2007).
doi: 10.1111/j.1467-7652.2007.00273.x
Castilho, A. et al. An oligosaccharyltransferase from Leishmania major increases the N-glycan occupancy on recombinant glycoproteins produced in Nicotiana benthamiana. Plant Biotechnol. J. 16, 1700–1709 (2018).
doi: 10.1111/pbi.12906
Teh, A. Y. H., Maresch, D., Klein, K. & Ma, J. K. C. Characterization of VRC01, a potent and broadly neutralizing anti-HIV mAb, produced in transiently and stably transformed tobacco. Plant Biotechnol. J. 12, 300–311 (2014).
doi: 10.1111/pbi.12137
Loos, A. et al. Glycan modulation and sulfoengineering of anti–HIV-1 monoclonal antibody PG9 in plants. Proc. Natl. Acad. Sci. 201509090 10.1073/pnas.1509090112 (2015).
Forthal, D. N. et al. Activity of Monoclonal Antibody 2G12 Binding and Cell-Mediated Anti-HIV Receptor γ Fc-Glycosylation Influences Fc Fc-Glycosylation Influences Fcg Receptor Binding and Cell-Mediated Anti-HIV Activity of Monoclonal Antibody 2G12. J Immunol Mater. Suppl. DC1.html J. Immunol. Univ. Manitoba 185, 6876–6882 (2010).
Moldt, B. et al. A Nonfucosylated Variant of the anti-HIV-1 Monoclonal Antibody b12 Has Enhanced Fc RIIIa-Mediated Antiviral Activity In Vitro but Does Not Improve Protection against Mucosal SHIV Challenge in Macaques. J. Virol. 86, 6189–6196 (2012).
doi: 10.1128/JVI.00491-12
Stelter, S. et al. Engineering the interactions between a plant‐produced HIV antibody and human Fc receptors. Plant Biotechnol. J. 1–13 https://doi.org/10.1111/pbi.13207 (2019).
Montero-Morales, L. & Steinkellner, H. Advanced Plant-Based Glycan Engineering. Front. Bioeng. Biotechnol. 6, 1–8 (2018).
doi: 10.3389/fbioe.2018.00081
Strasser, R. et al. Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotechnol. J. 6, 392–402 (2008).
doi: 10.1111/j.1467-7652.2008.00330.x
Pejchal, R. et al. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1 Departments of a Molecular Biology and. https://doi.org/10.1073/pnas.1004600107 .
Lewis, G. K. Qualitative and quantitative variables that affect the potency of Fc- mediated effector function in vitro and in vivo: considerations for passive immunization using non-neutralizing antibodies. Curr. HIV Res. 11, 354–64 (2013).
doi: 10.2174/1570162X113116660060
Baum, L. L. et al. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J. Immunol. 157, 2168–73 (1996).
pubmed: 8757343
Shields, R. L. et al. Lack of Fucose on Human IgG1 N -Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity. J. Biol. Chem. 277, 26733–26740 (2002).
doi: 10.1074/jbc.M202069200
Doi, E. & Jirgensons, B. Circular dichroism studies on the acid denaturation of gamma-immunoglobulin G and its fragments. Biochemistry 9, 1066–73 (1970).
doi: 10.1021/bi00807a003
Parker, C. E., Mocanu, V., Mocanu, M., Dicheva, N. & Warren, M. R. Mass Spectrometry for Post-Translational Modifications. Neuroproteomics (CRC Press/Taylor & Francis, 2010).
Hiatt, A. et al. Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc. Natl. Acad. Sci. USA 111, 5992–7 (2014).
doi: 10.1073/pnas.1402458111
Pettitt, J. et al. Therapeutic Intervention of Ebola Virus Infection in Rhesus Macaques with the MB-003 Monoclonal Antibody Cocktail. Sci. Transl. Med. 5, 1–6 (2013).
doi: 10.1126/scitranslmed.3006608
Bendandi, M. et al. Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin’s lymphoma. Ann. Oncol. 21, 2420–2427 (2010).
doi: 10.1093/annonc/mdq256
Doran, P. M. Foreign protein degradation and instability in plants and plant tissue cultures. Trends Biotechnol. 24, 426–432 (2006).
doi: 10.1016/j.tibtech.2006.06.012
Benchabane, M. et al. Preventing unintended proteolysis in plant protein biofactories. Plant Biotechnol. J. 6, 633–648 (2008).
doi: 10.1111/j.1467-7652.2008.00344.x
M., S. et al. In planta engineering of viral RNA replicons: Efficient assembly by recombination of DNA modules delivered by Agrobacterium. J. Appl. Biol. 101, 6852–6857 (2004).
Zhang, J. et al. PEAKS DB: De Novo Sequencing Assisted Database Search for Sensitive and Accurate Peptide Identification. Mol. Cell. Proteomics 11, M111.010587–M111.010587 (2012).
doi: 10.1074/mcp.M111.010587
Montefiori, D. C. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr. Protoc. Immunol. Chapter 12(Unit 12), 11 (2005).
pubmed: 18432938

Auteurs

Advaita Acarya Singh (AA)

Future Production: Chemicals, Council for Scientific and Industrial Research, Pretoria, South Africa.
Department of Plant and Soil Sciences, University of Pretoria, Pretoria, South Africa.

Ofentse Pooe (O)

Discipline of Biochemistry, University of KwaZulu-Natal, Durban, South Africa.

Lusisizwe Kwezi (L)

Future Production: Chemicals, Council for Scientific and Industrial Research, Pretoria, South Africa.

Therese Lotter-Stark (T)

Department of Production Animal Studies, University of Pretoria, Pretoria, South Africa.

Stoyan H Stoychev (SH)

Future Production: Chemicals, Council for Scientific and Industrial Research, Pretoria, South Africa.

Kabamba Alexandra (K)

Future Production: Chemicals, Council for Scientific and Industrial Research, Pretoria, South Africa.

Isak Gerber (I)

Future Production: Chemicals, Council for Scientific and Industrial Research, Pretoria, South Africa.

Jinal N Bhiman (JN)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, 92037, USA.

Juan Vorster (J)

Department of Plant and Soil Sciences, University of Pretoria, Pretoria, South Africa.

Michael Pauly (M)

Mapp Biopharmaceutical, San Diego, California, United States.

Larry Zeitlin (L)

Mapp Biopharmaceutical, San Diego, California, United States.

Kevin Whaley (K)

Mapp Biopharmaceutical, San Diego, California, United States.

Lukas Mach (L)

Department of Applied Genetics and Cell Biology, University of Natural Resources and Life Sciences, Vienna, Austria.

Herta Steinkellner (H)

Department of Applied Genetics and Cell Biology, University of Natural Resources and Life Sciences, Vienna, Austria.

Lynn Morris (L)

Centre for HIV and STIs, National Institute for Communicable Diseases of the National Health Laboratory Service (NHLS), Johannesburg, South Africa.

Tsepo Lebiletsa Tsekoa (TL)

Future Production: Chemicals, Council for Scientific and Industrial Research, Pretoria, South Africa. ttsekoa@csir.co.za.

Rachel Chikwamba (R)

Future Production: Chemicals, Council for Scientific and Industrial Research, Pretoria, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH